What is the Clinical Trials Activity initiative?

The Clinical Trials Activity initiative will invest $614.2 million over 10 years to increase clinical trial activity in Australia.

It incorporates the following Medical Research Future Fund (MRFF) grant opportunities:

Why is the Clinical Trials Activity initiative important?

This initiative is important because it:

  • gives patients across Australia more access to clinical trials
  • shows which treatments and medicines work best for patients
  • provides researchers with more opportunities to work with international colleagues in world-wide trials

What are the goals of the Clinical Trials Activity initiative?

This initiative aims to increase clinical trial activity in Australia, help patients access clinical trials, and enable researchers to bring international trials to Australian patients.

How will we meet these goals?

Our early funding priority areas are:

  • reproductive cancers
  • childhood brain cancer
  • neurological disorders
  • low-survival cancers and diseases
  • international clinical trial collaborations

 See the initiative snapshot for details of how we plan to meet these goals.

MRFF snapshot – Clinical Trials Activity

This snapshot shows this initiative at a glance. It includes budgets, early funding priorities and grant timelines, as at November 2019. Researchers and other stakeholders can use it to plan for upcoming opportunities and see how the initiative will be established, expanded and embedded over time.

Who works with us on the Clinical Trials Activity initiative?

The Medical Research Future Fund (MRFF) funds the initiative.

Our Health and Medical Research Office oversees this and other MRFF initiatives.

The National Health and Medical Research Council (NHMRC) administers this initiative.

Apply for funding

We will list grants on GrantConnect when they open. If you want GrantConnect to notify you about future MRFF grants:

  • register with them
  • enter ‘MRFF’ in the keyword section of your GrantConnect profile

Status

Upcoming grants

There are currently no upcoming grants. 

Open grant rounds

The 2021 Innovative Therapies for Mental Illness grant opportunity opened on 17 March 2021 and will close on 21 July 2021.

The 2021 International Clinical Trial Collaborations grant opportunity opened on 17 March 2021:

  • Round 1 Minimum Data will close on 25 August 2021
  • Round 1 Applications will close on 8 September 2021
  • Round 2 Minimum Data will close on 2 February 2022
  • Round 2 Applications will close on 16 February 2022.

Grants being assessed

We are currently assessing applications received under the:

  • 2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19 opportunity
  • 2020 Rare Cancers, Rare Diseases and Unmet Need General opportunity, and
  • 2020 International Clinical Trial Collaborations opportunity.

Grants awarded

We have awarded or announced the following grants under this initiative, as at 25 March 2021.

Funded Institution Project Name Chief Investigator/s Total Funding

Murdoch Children's Research Institute

A randomised control trial of positive end-expiratory pressure levels during resuscitation of preterm infants at birth (The POLAR Trial)

Associate Professor David Tingay

$1,387,654

The George Institute for Global Health

The SAHaRA Trial: Understanding the best red cell transfusion practice in patients with intracranial bleeding from a ruptured aneurysm

Associate Professor Anthony Delaney

$902,752

University of Western Australia

The Early valve replacement in severe ASYmptomatic aortic stenosis (EASY AS) trial

Professor Graham Hillis

$1,827,443

Macquarie University

The Australian-multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention (AU-ARROW) study

Professor Ralph Martins

$3,115,063

The University of Newcastle

Sunrise Australia – A randomised clinical trial of Single Use Negative pRessure dressing for Reduction in Surgical site infection following Emergency laparotomy

Doctor Peter Pockney

$782,256

La Trobe University

Prospective, multicentre trial evaluating FET-PET in high grade glioma

Professor Andrew Scott

$1,564,188

Monash University

A collaborative study of the Interfant network (Australian sites): the feasibility, safety and efficacy of the addition of Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged Acute Lymphoblastic Leukaemia (The Blin-fant Study)

Doctor Rishi Kotecha

$314,772

Monash University

A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukaemia (AML)

Associate Professor Andrew Wei

$1,507,785

Monash University

CAST – A Randomised Phase 3 Trial of Cyclophosphamide after Sibling Allogeneic Haematopoietic Stem Cell Transplant

Associate Professor David Curtis

$1,570,198

Monash University

The BLENDER Trial – Blend to Limit Oxygen in ECMO: A randomised Controlled Registry Trial

Professor David Pilcher

$753,355

Monash University

The DIAAMOND study: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset

Associate Professor Erica Wood

$1,750,726

Murdoch Children's Research Institute

The efficacy of rehabilitation for hereditary ataxias - a randomised controlled trial

Professor Martin Delatycki

$1,227,418

The University of Adelaide

Treatment of Severe Early Onset Intrahepatic Cholestasis of Pregnancy

Professor William Hague

$1,191,769

The University of Queensland

A platform clinical trial approach to the management of Mycobacterium abscessus complex (MABSC)

Professor Claire Wainwright

$2,091,178

The University of Queensland

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies

Professor Maher Gandhi

$1,642,389

The University of Queensland

Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer

Professor Janet Hardy

$1,363,040

University of Western Australia

BEAT-CF: Bayesian Evidence-Adaptive Trial to optimise management of Cystic Fibrosis

Associate Professor Thomas Snelling

$3,545,905

University of Melbourne

SpeechAtax: A rater-blinded randomised controlled trial of intensive home-based speech treatment for ataxia

Associate Professor Adam Vogel

$498,627

University of Melbourne

STOP-MSU: Stopping haemorrhage with Tranexamic acid commenced Prehospital in a Mobile Stroke Unit

Professor Stephen Davis

$1,285,820

University of New South Wales

CRISTAL: Cluster Randomised Trial of Apsirin versus Low molecular weight heparin for venous thromboembolism prophylaxis in joint replacement surgery, a registry-nested study

Professor Ian Harris

$934,848

University of New South Wales

Immunotherapy Targeting of Cytomegalovirus antigens in Glioblastoma: INTERROGATE-GBM

Associate Professor Kerrie McDonald

$1,446,002

University of Sydney

A randomised controlled trial, of N-Acetyl Cysteine, for premanifest Huntingtin gene expansion carriers (NAC-preHD)

Associate Professor Clement Loy

$1,905,227

University of Sydney

The BEST-Fluids study: Better Evidence for Selecting Transplant Fluids

Professor Steven Chadban

$1,117,150

 Murdoch Childrens Research Institute/Australian National University

A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics

Professor Anne-Louise Ponsonby

$887,072

Deakin University

The Candesartan Adjunctive bipolar Depression Trial - CADET

Professor Michael Berk

$2,428,397

La Trobe University

Improving muscle strength in young people with Prader-Willi syndrome

Professor Nora Shields

$874,179

Menzies School of Health Research

Improving outcomes of children and young adults with primary ciliary dyskinesia (PCD): a multi-centre, double-blind, double-dummy, 2x2 factorial, randomised controlled trial (RCT)

Professor Anne Chang

$2,375,118

Monash University

COZMOS: Phase I/Ib trial of COmbined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs

Doctor Jordan Hansford

$125,355

Monash University

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multicentre, stratified, double blind, placebo randomised controlled trial. (The EPO-TRAUMA trial)

Associate Professor Craig French

$3,509,303

Monash University

Evaluating the effectiveness and safety of sodium selenate as a disease modifying treatment for patients with behavioural variant Frontotemporal Dementia (bvFTD)

Professor Terence O'Brien

$1,604,184

Monash University

FaR-RMS: Frontline And Relapse study in RhabdoMyoSarcoma

Doctor Martin Campbell

$1,353,514

Monash University

Novel Venetoclax Combinations to Improve Outcomes in  Unfit Older Patients with Acute Myeloid Leukaemia

Associate Professor Andrew Wei

$1,380,298

Monash University

SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, Molecularly-Targeted CHK1/2i Therapy, in Combination with Cyclophosphamide or Gemcitabine for Children and Adolescents with Refractory or Recurrent Medulloblastoma Brain Tumours

Associate Professor Nicholas Gottardo

$226,284

The University of Queensland

A Randomised Phase II Trial of Adjuvant Avelumab in Patients with Early Stage Merkel Cell Carcinoma

Doctor Wen Xu

$1,632,096

The University of Queensland

An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma

Professor Maher Gandhi

$3,596,967

The University of Queensland

The TEACH-PD study: a Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes

Professor David Johnson

$2,383,207

University of Canberra

Evaluation of a bush medicine-based treatment for scabies in Australian Aboriginal children

Doctor Jackson Thomas

$1,294,542

University of Melbourne

The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma

Doctor Constantine Tam

$2,005,391

University of New South Wales

Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease (ACHIEVE) study

Associate Professor Martin Gallagher

$2,850,898

University of New South Wales

BEAT-Calci (Better Evidence And Translation in Calciphylaxis)

Associate Professor Meg Jardine

$2,201,944

University of New South Wales

Does Withholding Enteral feeds Around blood Transfusion reduce the incidence of necrotising enterocolitis (NEC) in very preterm infants? The international WHEAT Study

Professor Kei Lui

$1,606,826

University of New South Wales

MEMOIR: A multi-site placebo-controlled trial of memantine and graded motor imagery for complex regional pain syndrome

Associate Professor James McAuley

$922,314

University of Sydney

ALS Trials Australia (ALSTA) - to develop precision medicine

Professor Matthew Kiernan

$1,704,432

University of Sydney

MAGMA: Multi-Arm GlioblastoMa Australasia Trial

Doctor Craig Gedye

$1,273,632

University of Sydney

NAVMAN TRIAL: A multi-centre, dynamic, waitlist randomised controlled trial of patient navigators in children with chronic kidney disease

Associate Professor Germaine Wong

$1,093,681

University of Sydney

PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

Associate Professor Judith Trotman

$787,069

University of Sydney

PICCOG: PARP and Immune Checkpoint inhibitor Combination for relapsed IDH-mutant high-grade Glioma

Doctor Hao-Wen Sim

$1,391,472

La Trobe University

A Basket Study of Low Survival Cancers Treated with EGFR-ADCs

Associate Professor Hui Gan

$1,658,626

Monash University

Brain Oxygen Neuromonitoring In Australia And New Zealand Assessment (BONANZA) Trial

Associate Professor Andrew Udy

$1,084,852

Monash University

Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study

Professor Andrew Spencer

$1,682,836

Monash University

Improving survival in myelofibrosis

Professor Andrew Perkins

$1,733,327

University of Melbourne

Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC)

Doctor Shahneen Sandhu

$1,812,005

University of Sydney

mFOLFIRINOX and STEreotactic body radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally  AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG)

Associate Professor Andrew Kneebone

$1,512,808

Australian Clinical Trials Alliance

Strengthening the capacity, efficiency and effectiveness of Clinical Trials Networks through the Australian Clinical Trials Alliance

Not Applicable

$5,000,000

Murdoch Children's Research Institute

Pragmatic Paediatric Trial of Balanced versus Normal Saline Fluid in Sepsis (PRoMPT-BOLUS)

Professor Franz Babl

$3,055,619

University of Sydney

POLEM Trial: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study

Professor Timothy Price

$981,313

University of Sydney

Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial (COBRRA)

Doctor Vivien Chen

$1,057,840

University of Melbourne

Transfusion Triggers in Cardiac Surgery Australia trial (TRICS-IV)

Professor David Scott

$869,566

University of Melbourne

Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION)

Doctor Shahneen Sandhu

$3,230,670

Monash University

CONNECT 1903: A Pilot and Surgical Study of Larotrectinib for Disease Control in Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion

Associate Professor Nicholas Gottardo

$323,898

Monash University

MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients

Doctor Jordan Hansford

$879,904

Monash University

The TiNT Trial: A phase II clinical trial of trametinib in paediatric patients with neurofibromatosis type 1 associated progressive optic pathway gliomas

Associate Professor Geoffrey McCowage

$761,210

University of New South Wales

LOGGIC: A phase III, randomised international multi-centre trial for LOw Grade Glioma In Children and adolescents

Associate Professor David Ziegler

$1,128,498

Curtin University

A randomised control trial in subjects with early Alzheimer's disease in exploring if probucol supports cognitive function through improved cerebrovascular function

Professor John Mamo

$1,720,000

Deakin University

Does repetitive transcranial magnetic stimulation (rTMS), compared to sham rTMS, improve social communication in adolescents and young adults with autism spectrum disorder (ASD)?

Professor Peter Enticott

$1,903,208

Monash University

Sodium Selenate as a Disease Modifying Treatment for Progressive Supranuclear Palsy (Sodium Selenate for PSP)

Professor Terence O'Brien

$2,639,490

Monash University

Autoimmune Encephalitis - a rare and debilitating neurological illness affecting the Australian population. A study of the Australian Autoimmune Encephalitis Consortium

Doctor Mastura Monif

$2,092,825

Monash University

The Long-term Outcomes of Lidocaine Infusions for persistent PostOperative Pain in patients undergoing breast surgery (LOLIPOP) Trial

Professor Tomas Corcoran

$4,334,375

Murdoch Children's Research Institute

Study of Neck Injury Imaging in Children (SONIC): Improving the Diagnosis of Spinal Cord, Bone and Ligament Injuries Compared With Current Practice

Professor Franz Babl

$2,528,026

The University of Adelaide

Iodine supplementation in pregnancy to improve early childhood neurodevelopment: how much is enough?

Professor Maria Makrides

$3,235,960

University of Melbourne

Endovascular Brain Computer Interface for Independent Communication

Associate Professor Thomas Oxley

$1,481,180

The University of Newcastle

Reducing debilitating fatigue after stroke to improve Quality of Life

Professor Christopher Levi

$1,006,075

University of Sydney

Evaluation of a New Brief Intervention for Childhood Autism Spectrum Disorders

Professor Mark Dadds

$837,447

The University of Queensland

EnhAnCing treatment oUtcoMes after gynaEcological caNcer (ACUMEN): Using exercise to promote health after cancer therapy

Professor Alexandra McCarthy

$2,211,455

University of Sydney

PARAGON-II: Phase 2 basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms

Doctor Chee Khoon Lee

$1,995,422

University of Sydney

Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer: the ADELE study

Associate Professor Linda Mileshkin

$1,633,241

University of Sydney

HyNOVA - A randomised study comparing Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer

Doctor Rhonda Farrell

$686,674

Monash University

Australasian Resuscitation In Sepsis Evaluation: Fluid or Vasopressors in Emergency Department Sepsis (ARISE:Fluids) Trial

Professor Sandra Peake

$2,335,540

Monash University

Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women – A Randomised Controlled Trial (Bone Zone)

Associate Professor Neil Orford

$1,905,283

Murdoch Children's Research Institute

Clinical efficacy of ultrashort (1 dose) intravenous antibiotics compared to traditional duration (3 days) for children with complicated urinary tract infections: a multicentre randomised controlled trial

Associate Professor Penelope Bryant

$1,643,670

Murdoch Children's Research Institute

Does cannabidiol reduce severe behavioural problems in youth with intellectual disability? A randomised placebo-controlled trial

Associate Professor Daryl Efron

$883,485

The Council of the Queensland Institute of Medical Research

PRoCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling, compared with information alone, on participant-reported outcomes and use of medical services

Associate Professor Vanessa Beesley

$801,229

The University of Adelaide

Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort

Professor Timothy Hughes

$1,619,122

The University of Notre Dame Australia

Optimism in IBM: A dbRCT Phase III trial of Sirolimus in patients with Inclusion Body Myositis, to slow or stabilise otherwise relentless disease progression, as measured by the IBM Functional Rating Scale (IBMFRS)

Professor Merrilee Needham

$1,883,014

The University of Queensland

Implementation of Metformin theraPy to Ease DEcline of kidney function in PKD - the IMPEDE-PKD trial

Associate Professor Andrew Mallett

$2,572,403

The University of Queensland

The TELO-SCOPE study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis?

Professor Daniel Chambers

$1,828,446

The University of Queensland

Can intrapartum SildEnafil safely Avert the Risks of Contraction-induced Hypoxia in labour? iSEARCH – a pragmatic Phase 3 Randomised Controlled Trial

Professor Sailesh Kumar

$3,418,152

The University of Queensland

Targeting the gut microbiome as a treatment for Primary Sclerosing Cholangitis: The Queensland Clinical Network Study

Professor Gerald Holtmann

$1,631,020

The University of Queensland

Ataxia-telangiectasia: treating mitochondrial dysfunction with a novel form of anaplerosis

Professor David Coman

$2,459,666

University of Melbourne

Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a novel radiopharmaceutical targeting cancer-associated fibroblasts for the diagnosis and treatment of patients with Cancer of Unknown Primary: the FAPI-CUP trial

Associate Professor Linda Mileshkin

$2,387,925

University of Melbourne

A multi-centre randomised controlled trial of polysomnographic titration of non-invasive ventilation in motor neurone disease

Professor David Berlowitz

$3,480,677

University of New South Wales

AZA+: A multi-site phase 1/2 dose escalation/expansion trial combining azacitidine and defactinib for high-risk myelodysplastic syndrome patients who fail to respond to azacitidine alone

Professor John Pimanda

$3,328,736

University of Sydney

Optimising Q fever vaccination in Australia: Protecting our rural adolescents

Associate Professor Nicholas Wood

$1,772,624

University of Sydney

Structured exercise program to reduce fatigue in patients receiving dialysis: a preference-stratified adaptive trial (M-FIT)

Professor Allison Tong

$1,957,499

Total

$164,220,579

Related information

See a list of all MRFF grant recipients.

Contact

Medical Research Future Fund (MRFF) contact

Contact for more information about the Medical Research Future Fund (MRFF), or to provide feedback on the MRFF website.

General enquiries:
MRFF [at] health.gov.au
MRFF website or newsletter feedback:
HMRO [at] health.gov.au

View contact

National Health and Medical Research Council (NHMRC)

The National Health and Medical Research Council (NHMRC) funds high quality health and medical research to build research capability, support researchers, encourage the translation of research into better health outcomes and promote the highest ethical standards for health and medical research.

help [at] nhmrc.gov.au

View contact

Last updated: 
31 March 2021